Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alignment Healthcare (ALHC) Liabilities and Shareholders Equity (2020 - 2025)

Alignment Healthcare (ALHC) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $1.1 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity rose 59.27% year-over-year to $1.1 billion, compared with a TTM value of $3.0 billion through Dec 2025, up 6.18%, and an annual FY2024 reading of $782.1 million, up 32.13% over the prior year.
  • Liabilities and Shareholders Equity was $1.1 billion for Q3 2025 at Alignment Healthcare, up from $1.0 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q3 2025 and bottomed at $591.9 million in Q4 2023.
  • Average Liabilities and Shareholders Equity over 5 years is $741.7 million, with a median of $692.3 million recorded in 2024.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 86.38% in 2021, then dropped 16.87% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $630.9 million in 2021, then grew by 0.47% to $633.9 million in 2022, then dropped by 6.62% to $591.9 million in 2023, then skyrocketed by 32.13% to $782.1 million in 2024, then skyrocketed by 40.99% to $1.1 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ALHC at $1.1 billion in Q3 2025, $1.0 billion in Q2 2025, and $895.6 million in Q1 2025.